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ABSTRACT 
Objective: To develop bilayer matrix tablet of Doxofylline by providing a loading dose followed by the maintenance dose that suppose to enhance 
the therapeutic efficacy the drug for acute and sustainable asthma. 
Methods: Both immediate release layer and sustained release layer were prepared by wet granulation methods. Different Pre compression and post 
compression characterization of the tablet were carried out. Swelling studies were carried out for all the formulation. To optimise the immediate release 
layer, similarity (f2) and difference factor (f1
Results: Pre compression and post compression parameters satisfied with pharmacopeia specifications. The formulation that contained highest 
percent of HPMC had highest swelling index. Formulation DBMF
) were calculated and optimised IR formulation was used for all formulations of bilayer tablet. In-vitro 
release studies were carried out in USP II paddle type dissolution apparatus for different formulations and release kinetic studies were carried out 
different kinetic model. FTIR and DSC studies were carried out for pure drug Doxofylline, IR layer and SR layer of optimised formulation to know the 
physical and chemical compatibility of drug and excipients. Accelerated stability studies were carried out to confirm the stability of dosage forms.  
6
Conclusion: Doxofylline bilayer matrix tablets were successfully developed and can be used as an alternative to the conventional dosage form 
because it can be therapeutically beneficial for management of asthma. 
 showed an initial release of 44% of drug within one hour as the loading dose and 
remaining drug were sustained release up to 12 h. Release kinetic followed Hixon-Crowell kinetic model with drug release mechanism quasi-fickian 
diffusion. From accelerated stability studies no significant changes in physicochemical properties were noticed.  
Keywords: Bilayer tablet, Sustained release, Doxofylline, Immediate release, HPMC, Eudragit.  
 
INTRODUCTION 
Bilayer tableting technology has gained popularity in recent times, 
as bilayer tablets offer several advantages over conventional tablets. 
Usually conventional dosage form produce wide ranging fluctuation 
in drug concentration in the blood stream and tissues with 
consequent undesirable toxicity and poor efficiency. This factor such 
as repetitive dosing and unpredictable absorption led to the concept 
of controlled drug delivery systems.  
The goal in designing sustained or controlled delivery systems is to 
reduce the frequency of the dosing or to increase effectiveness of the 
drug by localization at the site of action, reducing the dose required 
or providing uniform drug delivery. The primary objective of 
sustained release drug delivery is to ensure safety and to improve 
efficacy of drugs as well as patient compliance. Bilayer tablet is 
suitable for sequential release of two drugs in combination, separate 
two incompatible substances and also for sustained release tablet in 
which one layer is immediate release as an initial dose and the 
second layer is maintenance dose [1]. 
The bilayer tablet concept has long been utilized to formulate 
biphasic release of drugs [2]. Such a bilayer tablet contains a first 
release layer and a sustain release layer. The first releasing layer 
leads to rapid release of the drug, so as to reach high serum 
concentration in a short period of time that is called as loading dose. 
The sustain release layer of the bilayer tablet releases the drug for 
the prolonged period of time to maintain the effective concentration 
of drug within the therapeutic index [3].  
This release pattern is required for successful treatment in many 
therapies, primarily when maximum relief needs to be achieved as 
soon as possible, and is followed by a sustained release phase to 
avoid repeated drug administration. So bilayer matrix tablet 
containing a single drug having one layer as fast release layer and 
another as sustained release layer will be beneficial for the chronic 
disease like asthma, diabetes, hypertension and inflammation that 
require immediate effect as well as maintenance therapy [4].  
Asthma and COPD (Chronic Obstructive Pulmonary Disease) are the 
most common life threatening pulmonary disease that requires 
constant monitoring. Doxofylline, a methyl xanthine derivative that 
works by inhibition of phosphodiesterase IV activities, has recently 
drawn attention because of its better safety profile and similar 
efficacy over the most widely prescribed analogue, theophylline, 
indicated for asthma and chronic obstructive pulmonary disease due 
to decreased affinities towards adenosine A1 and A2 receptors. 
Doxofylline is chemically designated as 7-(1, 3 dioxolone-2-yl 
methyl) theophylline. Presence of a dioxolane group in position C-7 
differentiates it from theophylline. Doxofylline is an anti-tussive and 
bronchodilator used for maintenance therapy in patients suffering 
with asthma and chronic obstructive pulmonary disease (COPD) and is 
extensively metabolized in the liver by demethylation and oxidation to 
an extent of 80-90% and 48% plasma protein bound. Elimination half 
life (t½) is around 6-7 h and<4% of an administered dose of 
Doxofylline is excreted unchanged in the urine. The daily dose is 200-
400 mg two to three times in a day. Doxofylline is coming under class 
III of BCS classification and oral absorption is 62.2%. It is having 
solubility of 12 mg/ml in water and having PKa
The objective of the present study was to develop bilayer tablets of 
Doxofylline with a fast-release layer using cross carmellose as 
superdisintegrant and a sustaining layer using hydroxyl propyl 
methylcellulose (HPMC K4M, K15M) and Eudragit RSPO, RLPO as 
polymeric retardant materials. This formulation is suppose to be 
superior to available Doxofylline conventional and sustained release 
tablet marketed formulation as the former required frequent dosing 
and later having low initial dose that may leads to slow unset of 
action. The formulation under study is suppose to deliver an initial 
loading dose from immediate release layer followed by maintenance 
dose from sustained release layer that may be useful for better 
therapeutic management of acute and sustainable asthmatic 
conditions. Different proportion of HPMC K4M, K15M and Eudragit 
 9.87 [5]. 
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RSPO, RLPO were selected to form sustained release layer for 
different bilayer formulation to optimise drug release profile [6]. 
MATERIALS AND METHODS 
Materials 
Doxofylline was procured as a gift sample from Dr. Reddy’s 
Laboratories Hyderabad, India. The super disintegrant cross 
carmellose sodium was also obtained as a gift sample from Dr. Reddy’s 
laboratories Pvt. Ltd. HPMC K4M, HPMC K15M and Eudragit RSPO, 
RLPO polymers were received as gift sample from Glenmark Pharma, 
Nasik, India. The diluent Micro crystalline cellulose (MCC) and lactose 
was purchased from Otto Manufacturers. PVP K30, Talc and 
magnesium Stearate were purchased from S. D. fine chemicals Pvt. Ltd’ 
Mumbai, India. All the ingredients were of laboratory grade. The 
distilled water used in the process of research work was prepared by 
double distillation process in the laboratory. 
Methods 
Calculation of dose of drug in a bilayer sustained release tablets 
containing single drug 
The total dose of Doxofylline for a bilayer sustained release tablet 
formulation containing an immediate release layer and sustained 
release layer was calculated by the following four equations using 
available pharmaco kinetic data from a design of one compartment 
model with simultaneous release of loading dose and maintenance 
dose with a zero-order release as described by Robison and Eriksen: 
[6, 7] 
K0 = DIKE … … … … … (1) 
DM = K0T … … … … … (2) 
DL = DI −  K0Tmax … … … … … (3) 
DT =  DL + DM … … … … … (4) 
DM  = maintenance dose; T = time for sustained action; Tmax = Time to 
reach peak plasma concentration; elimination half-life (t1/2) of 
Doxofylline is 7–10 h (average 8.5); time to reach peak plasma 
concentration (Tmax) = 1.19 h; initial dose (DI) = 400 mg. 
Elimination rate constant KE = 0.693 t1/2�  
= 0.693/8.5h 
= 0.082 h-1 
Zero-order release constant K0 = DI × K
= 400 mg × 0.082 h
E 
= 32.8 mg/h 
-1  
Loading dose DL  = DI − (K0 × Tmax
= 400–(32.8 × 1.19 h) 
) 
= 400–39.032 
= 360.97 mg 
So, maintenance dose = Total dose–loading dose 
= 800 mg–360.97 mg 
= 439.03 mg. 
Hence, the matrix tablet should contain a total dose of 800 mg for 12 
h SR dosage form and it should release 400 − 39.032 = 360.97 
(45.12%) mg in the 1st hour like conventional dosage form and the 
remaining dose (800 − 360.97) in remaining 11 h, i.e. 439.03 
(54.88%) mg or 39.91 (4.98%) mg per hour up to 12 h. 
Formulation of bilayer matrix tablets of doxofylline 
Bilayer matrix tablets of Doxofylline consist of two types of granules 
i.e. the first layer consists of the optimized immediate release layer 
granules and for second layer, different proportion of polymers were 
used for sustained release layer to optimise drug release profile 
according the need. For preparation of both immediate release layer 
and sustained release layer granules; wet granulation methods were 
adopted. Accurate quantities of all ingredients were weighed and 
passed through sieve no #80 before their use in formulations. A 
lump wet mass was produced by adding the required quantity of 
distilled water as granulating agent. The aggregates formed were 
initially dried for 5-10 min to reduce moisture level and to prevent 
sticking with sieve. The aggregates were passed through sieve # 20 
to get wet granules. The granules were then dried at 40o
 
 C for 20 min 
to reduce moisture content upto 2-5 %. After lubrication with 
magnesium stearate and talc; the granules of both the layer were 
evaluated for an angle of repose, bulk density, compressibility index 
and Hausner’s ratio; prior to compression. The evaluated granules 
along with the immediate release layer granule were compressed 
into bilayer tablets on a 10-station rotary bilayer tablet punching 
machine using 12 mm concave punches. Each tablet contains 361 mg 
of Doxofylline in an immediate release layer and 439 mg of 
Doxofylline in sustained release layer. The composition for different 
formulations of an immediate release layer and sustained release 
layer was shown in table 1 and table 2 respectively. Same methods 
were followed for all the formulations. The prepared bilayer tablet 
formulations were evaluated for various post compression 
parameters like average thickness, weight variation, hardness, 
friability, drug content study and in vitro dissolution studies [8]. 
Table 1: Compositions of immediate release layer for Doxofylline bilayer matrix tablets 

























DIRF 361 1 25 39 50 10 - - 5 10 500 
DIRF 361 2 25 29 50 20 - - 5 10 500 
DIRF 361 3 25 19 50 30 - - 5 10 500 
DIRF 361 4 25 39 50 - 10 - 5 10 500 
DIRF 361 5 25 29 50 - 20 - 5 10 500 
DIRF 361 6 25 19 50 - 30 - 5 10 500 
DIRF 361 7 25 39 50 - - 10 5 10 500 
DIRF 361 8 25 29 50 - - 20 5 10 500 
DIRF 361 9 25 19 50 - - 30 5 10 500 
DIRF 361 10 25 29 50 - 10 10 5 10 500 
DIRF 361 11 25 19 40 - 10 20 5 10 500 
DIRF 361 12 25 19 40 - 20 10 5 10 500 
 
Evaluation 
Drug excipients compatibility studies 
Drug excipients compatibility studies were done by FTIR and DSC 
Fourier transforms infrared (FTIR) spectroscopy [9] 
Fourier transform infrared (FTIR) study was performed to verify 
any physical or chemical interaction between the pure drug and the 
excipients used for formulation. In the present investigation FTIR 
Panda et al. 
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spectrum of pure drug Doxofylline, physical mixture of drug and 
excipients used for IR layer and SR layer of optimised formulation 
was carried out. These were performed by potassium bromide (KBr) 
pellet method.  
The samples were triturated with KBr and pellet was prepared 
by setting the pressure to 100 kg/cm2
Differential scanning calorimetric (DSC) analysis [10] 
 for 2 min. The obtained 
pellet was analyzed in FTIR 8400S, Shimadzu, Japan. KBr 
background was obtained initially before analysis of test 
samples. 
The DSC analysis of pure drug Doxofylline, physical mixture of drug 
and excipients used for IR layer and SR layer of optimised 
formulation was carried out using a Shimadzu DSC 60, Japan; to 
evaluate any possible drug-excipients thermal interaction. Exactly 
weighed 5 to 6 mg samples were hermetically sealed in aluminium 
crucible and heated at the constant rate of 10 °C/min over a 
temperature range of 40 to 300 °C. Inert atmosphere was 
maintained by purging nitrogen gas at a flow rate of 50 ml/min. 
 
Table 2: Composition of sustained release layer for Doxofylline bilayer matrix tablets 









RSPO (mg)  
Eudragit 












wt. (mg)  
DSRF1 439   100 - 30 - 16 45 7 13 650 
DSRF2 439   - 100 30 - 16 45 7 13 650 
DSRF3 439   100 - - 30 16 45 7 13 650 
DSRF4 439   - 100 - 30 16 45 7 13 650 
DSRF5 439   80 - 50 - 16 45 7 13 650 
DSRF6 439   - 80 50 - 16 45 7 13 650 
DSRF7 439   80 - - 50 16 45 7 13 650 
DSRF8 439   - 80 - 50 16 45 7 13 650 
DSRF9 439   50 50 30 - 16 45 7 13 650 
DSRF10 439   50 50 - 30 16 45 7 13 650 
 
Evaluation of pre compression parameters [10, 11] 
The prepared dry granules of both the layers of Doxofylline bilayer 
matrix tablets were taken and evaluated for different pre 
compression parameters like angle of repose, bulk density, tapped 
density, Carr’s index, and Hausner’s ratio to ensure good flow 
properties of the same during tablet compressions. All the pre 
compression parameters are outlined below 
Angle of repose (θ) 
Angle of repose is indicated as maximum angle possible between the 
surface of a pile of granules and the horizontal plane. The granules 
were allowed to flow through the funnel fixed to a stand at the 
definite height (h). The angle of repose was then calculated by 





Where θ was called as an angle of repose, h and r were height and 
radius of the granule heap respectably. According to the 
specifications the angle of repose value less than 25 ° indicates 
excellent flow whereas angle “between” 25 °-30 ° indicates good 
flow. The angle “between” 30 °-40 ° indicates passable flow and 
angle greater than 40 ° indicates very poor flow.  
Bulk density and tapped density [12] 
Both the loose bulk density (LBD) and tapped bulk density (TBD) of 
prepared granules of an immediate release layer and sustained 
release layer of all the formulations were determined. The quantity 
of 2 g of granules from each formula, previously lightly shaken to 
break any agglomerates formed; were introduced into a 10 ml 
measuring cylinder. After the initial volume was observed, the 
cylinder was allowed to fall under its own weight on to a hard 
surface from the height of 2.5 cm at second interval.  
The tapings were continued until no further changes in volume were 
noted. The process was carried out thrice for each formulation and 
average was taken. Standard deviation was calculated to know the 
variation in the formulation. LBD and TBD of prepared granules 
were calculated using the following formulas.  
 
LBD =weight of the granule 
volume of the packing
 
TBD = weight of the granule 
tapped volume of the packing
 
Compressibility index (Carr’s index)  
Compressibility index (Carr’s index) of prepared Doxofylline 
granules for immediate release and sustained release layer were 
calculated by following formula  
Carr’s index (%) = TBD−LBD
TBD
 × 100 
According to the specification, the Carr’s index values “between” 5-
15 indicates excellent flow whereas between 12-16 indicates good 
flow. Values “between” 18-21 indicate fare-passable whereas 
between 23-25 indicates poor flow whereas values between 33-38 
indicates very poor flow and greater than 40 indicates extremely 
poor flow [12].  
Hausner’s ratio  
The Hausner’s ratios of prepared Doxofylline granules for immediate 
release and sustained release layer were determined by following 
formula.  
Hausner’s ratio = TBD
LBD
 
According to specifications values less than 1.25 indicate good flow 
(=20% of Carr’s index), where as greater than 1.25 indicates poor 
flow (=33% of Carr’s index). Between 1.25 and 1.5, added glidant 
normally improves flow [13].  
Evaluation of doxofylline bilayer matrix tablets 
Thickness  
Thickness of each tablet was measured by using digital Vernier 
Callipers (Mitutoyo digital Thickness Gauge, Mitutoyo, Japan). Ten 
tablets of Doxofylline bilayer matrix tablets from each formulation 
were randomly selected and used for thickness determination. The 
results were expressed as mean values of ten readings, with 
standard deviations. According to specification tablet thickness 
should be controlled within a±5% variation of standard value [14]. 
Tablet hardness  
All the formulations of Doxofylline bilayer matrix tablets were 
subjected to hardness measurement by using Monsanto hardness 
tester (Cad Mach). From each formulation the crushing strength of 
ten tablets with known weights was recorded in kg/cm2 and 
average, were calculated and presented with standard deviation. 
According to specifications of USP hardness values of 5-7 kg/cm2 for 
bilayer matrix tablet is considered as acceptable limit [14]. 
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Previously weighed ten bilayer matrix tablets of Doxofylline from 
each batch were taken in Roche friabilator (Secor India). After100 
revolutions of friabilator, tablets were recovered. The tablets were 
then made free from dust and the total remaining weight was 





Where Wi and Wf
Weight variation test  
 were the initial and final weight of the tablets 
before and after friability test. For compress tablet, lose between 0.1 
to 0.5 % and maximum up to 1% of the tablet weigh are consider 
acceptable [14]. 
According to USP monograph, the weight variation tolerance limit 
for the uncoated tablet having average weight 130 mg or less is 10% 
whereas for average weight between 130-324 mg is 7.5% and for 
average weight more than 324 mg is 5%. For the tablet to be 
accepted, the weight of not more than two tablets deviate from the 
average weight by not more than 7.5% and no tablet deviates by 
more than 15%. All formulated Doxofylline bilayer matrix tablets 
were evaluated for weight variation as per USP monograph. Twenty 
tablets were weighed collectively and individually using an 
electronic balance (Citizen CTG-302). The average weight and 
percent variation of each tablet was calculated [15].  
Content uniformity  
Twenty Doxofylline bilayer matrix tablets were taken and triturated 
to form powder and powder equivalent to one tablet was taken and 
dissolved in 100 ml of phosphate buffer PH
Swelling index (SI) 
 6.8 and heated at 37 °C 
for 60 min with stirring. The solution was filtered, suitably diluted 
and the Doxofylline content was measured by using UV 
Spectrophotometer (Analytical Technologies Ltd. Spectro 2080) at 
λmax of 274 nm. Each measurement was carried out in triplicate and 
the average drug content in the Doxofylline bilayer matrix tablets 
was calculated [15]. 
The swelling behaviour of all formulations of Doxofylline bilayer 
tablet was measured by studying its weight gain in the dissolution 
medium under study. The swelling index of selected bilayer matrix 
tablets were determined by placing the tablets in the basket of 
dissolution apparatus maintaining dissolution medium at 37±0.5 °C. 
After every one hour interval and up to 12 h, each dissolution basket 
containing tablet was withdrawn and blotted with tissue paper to 
remove the excess water and weighed on the analytical balance 
(Shimadzu, Ax 120). The experiment was performed in triplicate for 
each time point. Swelling index was calculated by using the following 
formula [16]. 




Where Wf and Wi
In-vitro drug release study 
 is called as wet and dry weight of the tablet 
respectively.  
The in vitro release studies was conducted for all Doxofylline bilayer 
matrix tablet formulations using eight station USP dissolution rate 
test apparatus type-II (LABINDIA DS 8000, Mumbai, India.) at 
37±0.5 °C. A proper simulation of gastrointestinal (GIT) condition 
was maintained by altering the PH of dissolution medium at different 
time intervals following two step dissolution conditions. To simulate 
the physiological conditions of GIT, first 2 h of dissolution was 
carried out in 900 ml of simulated gastric fluid (SGF, 3.2 mg/ml 
pepsin in 0.05 M HCl, PH 1.2) and the rest of the time in 900 ml of 
simulated intestinal fluid (SIF, 10 mg/ml pancreatic fluid in 
Sorensen’s phosphate buffer, PH
Calculation of similarity and difference factors for Doxofylline 
immediate release layer 
 7.4) at regular intervals of time, the 
aliquots were withdrawn and analyzed for drug using the UV-Visible 
spectrophotometer (Analytical Technologies Ltd. Spectro 2080) at 
λmax of 273 nm and 274 nm for SGF and SIF respectively. After each 
sampling an equal volume of fresh dissolution fluid was added to the 
dissolution medium. All the dissolution studies were repeated three 
times [17]. 
The optimized formulation for immediate release layer was chosen 
according to comparative dissolution study with a reference 
marketed product of DOXOBRON TAB (Invision) containing 
Doxofylline 400 mg, employing the similarity factor (f2) and 
difference factor (f1
The similarity factor (f




) adopted by the U. S. Food and Drug 
Administration (FDA) was used to evaluate the similarity in release 
profiles between the two pharmaceutical preparations. The 
similarity factor, which is a logarithmic transformation of the sum 
squared error of differences between the test preparation and 
reference preparation, was calculated by the following equation:  









t  and Tt are the accumulated release rates of the reference 
preparation and test preparation at the predetermined time points, 
respectively, and n represents the number of the time points. The 
value of the similarity factor is between 0 and 100. The value 100 
indicates that the test and reference profiles are identical; the more 
it approaches 0, the more dissimilarity of the two preparations 
occurs. Generally, if f2>50, the release profiles are considered to be 
similar, and the larger the f2
Difference factor (f
 value, the higher the similarity.  
1
Dissolution profile was considered satisfactory if f1 values lies below 
15 (nearing zero, more it approaches towards zero more similarity 
is the product [18, 19]. 
) measures the percent error between two drug 





Determination of the release kinetics from the in vitro drug 
release profile [19, 20] 
The rate and mechanism of release of Doxofylline from prepared 
bilayer tablets were analyzed by fitting the dissolution data into 
following exponential equations. 
Zero order release equation is expressed as 
Q = K0 t  
Where Q is the amount of drug released at time t and K0
The first order equation is expressed as 




 is the zero 
order release rate constant. 
Where, K1




 is the first order release rate constant. 
Where, K2
The dissolution data was also fitted to the Korsmeyer-Peppas 
equation, which is often used to describe the drug release behaviour 
from polymeric systems as follows 
log �Mt M∞� � = log K + n logt 
 is the diffusion rate constant. 
Where Mt is the amount of drug released at time t, M∞ is the amount 
of drug release after infinite time, K is a release rate constant and n 
is the diffusion exponent indicative of the mechanism of drug 
release. 
Panda et al. 
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For matrix tablets, if the exponent n<0.5, then the drug release 
mechanism is quasi-fickian diffusion (If n = 0.5 then fickian diffusion 
and if the value is 0.5<n<1, then it is anomalous diffusion coupled 
with erosion. An exponent value of 1 is indicative of Case-II 
transport or typical zero-order and n>1 non-fickian super Case II). 
The diffusion exponent was based on Korsmeyer-Peppas equation.  
Hixson-Crowell recognized that area of the particle is proportional 





3� = Kst 
Where Wo is the initial amount of drug, Wt is the remaining amount 
of drug in dosage form at time t, and KS
The tablets of optimized batch (DBMF
 is a constant incorporating 
the surface volume relation. The graphs are plotted as cube root of 
percent drug remaining versus time [21, 22]. 
Stability studies of optimised formulation 
6) were packed in air tight 
bottles and subjected to accelerated stability studies according to 
ICH guidelines. The accelerated condition that was chosen for 
stability study at 40 oC±2 o
RESULTS AND DISCUSSION 
C/75%±5% RH using humidity control 
oven NEC 210R10 (Newtronic Instruments, India) for 90 d. After 
that period the product was evaluated for friability, hardness, weight 
variation, thickness, drug content and in vitro release study [23, 24]. 
Compatibility studies by FTIR and DSC 
By comparing the spectra of Doxofylline, IR and SR layer of 
optimised formulation (DBMF6), the sharp peaks that appear in 
spectra of Doxofylline at ̴  3110 cm-1 due to presence of aliphatic N-H 
stretching functional group also appears in IR layer and SR layer at ̴  
2916 cm-1and 3110 cm-1
The characteristic infrared absorption peaks of Doxofylline at  ̴  1700 
cm
respectively.  
-1 (C=O stretch), at  ̴  1656 cm-1 (C=C stretch), at  ̴  1547 cm-1 (C=N 
stretch), at  ̴  1477 cm-1 (C-H bend) and at  ̴  1190 cm-1 (C-N vibration) 
were also present in the physical mixture (drug and excipients of 
both IR and SR layer) with no shifting in the major peaks that 
indicate there were no interaction occurred between the Doxofylline 
and excipients used in the preparation of different bilayer 
formulations. Therefore the drug and excipients are compatible to 
form stable formulations under study. The FTIR spectra of pure drug 
Doxofylline and physical mixture used for IR layer and SR layer in 
optimized formulation DBMF6
 
 were obtained and shown in fig. 1. 
 
Fig. 1: Compatibility studies through FTIR analysis 
 
DSC thermogram of pure drug Doxofylline and physical mixture used for IR layer and SR layer in optimized formulation DBMF6 were obtained and 
shown in fig. 2. It was observed that the endothermic peak appeared at 146 °C for pure drug Doxofylline also appeared at 148 °C and 151 °C in 
optimised formulation of IR and SR layer respectively which indicate that the formulation is thermodynamically stable because the formulation 
required slightly more heat than pure drug due to presence of various excipients. Appearance of other peaks due to presence of other excipients in 
the formulations. The DSC thermogram of pure drug and the formulations showed there was no major shifting i. e from endothermic to exothermic 
with appearance of major thermal peaks in the optimised formulation.  
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Fig. 2: Compatibility studies through DSC analysis 
 
The loose bulk densities of Doxofylline immediate release layer and 
sustained release layer granules of all formulations were found to be 
in the range of 0.399 to 0.541 g/cm3 and 0.487±0.04 to 0.532±0.02 
g/cm3 respectively. The tapped densities were found to be in 
between 0.475 to 0.589 g/cm3 and 0.512±0.08 to 0.593±0.06 g/cm3
This indicates good packing capacity of granules. Bulk density and 
tapped density measurements found that the density of granules 
depends on particle packing and that density changes as the granules 
consolidates.  
 
for IR and SR layer respectively.  
Values of Carr’s index for all the formulations and for both the layer 
were found below 16% that usually indicates good flow 
characteristics. In all formulations, the Hausner’s ratios values were 
found “between” 1.07 to 1.21 for IR layer and “between” 1.05 to 1.15 
that indicates good flow characteristics.   
Angle of repose is suited for particle>150 μm. The angle of repose of 
all formulations fell within the range of 18.62 ° ± 0.12 to 22.65 ° ± 
0.12 for IR layer and 18.51 °±0.16 to 23.92 °±0.13 for SR layer i.e. dry 
granules of Doxofylline immediate release and sustained release 
layer showed good flow properties. 
 
Table 3: Evaluation of doxofylline immediate release layer granules (DIRF1–DIRF10
F. No.  
) 
Bulk density  
(g/cm3
Tapped density  
)  (g/cm3
Angle of repose (θ)  
)  




DIRF1 0.432±0.05    0.521±0.06  22.41±0.11  17.08  1.21  
DIRF2 0.490±0.06    0.584±0.05  21.53±0.10  16.09  1.19  
DIRF3 0.465±0.08    0.502±0.06  20.91±0.14  7.37  1.07  
DIRF4 0.501±0.06    0.573±0.08  19.62±0.16  12.57  1.14  
DIRF5 0.423±0.05    0.492±0.07  22.84±0.18  14.02  1.16  
DIRF6 0.399±0.08    0.475±0.05  18.62±0.12  16.01  1.19  
DIRF7 0.482±0.09    0.521±0.08  21.52±0.11  7.48  1.08  
DIRF8 0.541±0.07    0.589±0.07  20.63±0.13  8.15  1.09  
DIRF9 0.477±0.05    0.524±0.06  19.49±0.14  8.97  1.10  
DIRF10 0.472±0.06    0.525±0.08  22.28±0.15  10.10  1.11  
DIRF 0.482±0.03 11 0.521±0.06 19.46±0.14 7.48  1.08  
DIRF 0.490±0.08 12 0.584±0.09 22.65±0.12 16.09  1.19  
All values are expressed as mean±SD; (n=3) 
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Table 4: Evaluation of doxofylline sustained release layer granules (DSRF1–DSRF10
F. No.  
) 
Bulk density  
(g/ml)  
Tapped density  
(g/ml)  




DSRF1 0.532±0.02    0.564±0.05  20.41±0.19  05.67  1.06  
DSRF2 0.520±0.03    0.593±0.06  21.54±0.14  12.31  1.14  
DSRF3 0.501±0.02    0.578±0.06  23.92±0.13  13.32  1.15  
DSRF4 0.508±0.06    0.582±0.07  20.66±0.12  12.71  1.15  
DSRF5 0.498±0.04    0.556±0.04  21.88±0.14  10.43  1.12  
DSRF6 0.496±0.05    0.532±0.07  19.69±0.15  06.77  1.07  
DSRF7 0.487±0.04    0.512±0.08  18.51±0.16  04.88  1.05  
DSRF8 0.512±0.06    0.568±0.08  22.62±0.15  09.86  1.11  
DSRF9 0.518±0.05    0.549±0.05  19.08±0.14  05.65  1.06  
DSRF10 0.519±0.07    0.562±0.06  20.17±0.15  07.65  1.08  
All values are expressed as mean±SD; (n=3) 
 
The physical parameters of the all the formulations of Doxofylline 
bilayer sustained released matrix tablets were found to be 
satisfactory. The tablets from all factorial batches were white, 
circular. The surface texture was smooth. Typical tablet defects, such 
as capping, chipping and picking, were not observed. The average 
thicknesses of the tablets was ranged between 5.82±0.11 to 
5.90±0.14 mm and it was found to be within limit of deviation from 
an average value (not more than 5%). 
Weight variations for different formulations were ranged between 
1147±3.56 to 1154±4.24 mg. The weight variation for all the 
formulations within limits indicates uniformity in tablet 
compression and consequently content of drug in a unit. The average 
percentage deviation of all tablet formulations was found to be 
within the limit, and hence all formulations passed the test for 
uniformity of weight as per official requirement.  
The hardness of all the Doxofylline bilayer sustained released matrix 
tablets formulations were ranged from 7.54±0.7 to 8.98±0.6 kg/cm2
The percentage friability of all the formulations was ranged from 
0.63±0.06% to 0.41±0.05 %. In the present study, the percentage 
friability for all for formulations was within the prescribed limits that 
indicated the product is resistant to wear and tear during handling and 
transportation. The percentages of drug content for Doxofylline bilayer 
sustained released matrix tablet formulations (DBMF
 
which indicated good handling and transportation characteristics of 
tablets under study.  
1 to DBMF10
The physicochemical characterizations of different batches of bilayer 
sustained released tablets are given in table 3. 
) were 
found to be in between 98.39±1.4 % to 102.42±1.2% (i.e. variation 
of±4%) which were within the acceptable limits. The value ensures good 
uniformity of the drug content in the tablet. 
Swelling study was performed on all the formulations (DBMF1 to 
DBMF10) upto 12 h. The formulation containing more concentration 
of HPMC K4M, HPMC K15M showed higher swelling indices due to 
higher hydrophilicity and more water uptake of the polymers. But 
reverse is observed with the formulations containing higher 
percentage of Eudragit RSPO and RLPO, as it is a hydrophobic 
polymer. The formulations (DBMF9 and DBMF10) containing the 
combination of both the grade of HPMC in equal proportion, showed 
higher swelling index. Among all the formulations, DBMF10 that 
contained around 8% of HPMCK4M, 8% of HPMCK15M and 5% of 
Eudragit RLPO showed highest swelling index than other 
formulations. Formulations DBMF5, DBMF6, DBMF7, and DBMF8
 
 
that contained more % of Eudragit had lower swelling index as 
compare to other formulations as Eudragit is a hydrophobic 
polymer. The result of swelling index is shown in fig. 2. 
Table 5: Evaluation of postcompression parameters of doxofylline bilayer matrix tablets 
F. No.  Average hardness  
(kg/cm2
Average weight  
)  variation (%)  
Average friability  
(% w/w)  
Average  
thickness (mm)  
Drug content uniformity 
(%) 
DBMF1 7.97±0.6   1152±4.32 0.63±0.05  5.89±0.12  102.42±1.2 
DBMF2 7.54±0.7    1151±3.54 0.64±0.06  5.90±0.14  98.39±1.4 
DBMF3 7.89±0.9    1153±4.27 0.51±0.07  5.89±0.18 99.75±1.6 
DBMF4 7.95±0.8    1148±3.61 0.47±0.08  5.82±0.16  100.95±1.2 
DBMF5 8.02±0.6    1147±4.82 0.63±0.06  5.84±0.12  101.48±1.1 
DBMF6 8.01±0.8    1152±3.43 0.48±0.04  5.82±0.11  101.54±1.5 
DBMF7 8.00±0.7    1147±3.56 0.41±0.05  5.84±0.15  98.84±1.4 
DBMF8 8.91±0.9    1148±3.72 0.46±0.06  5.83±0.14  99.36±1.6 
DBMF9 8.98±0.6    1153±3.93 0.42±0.08  5.85±0.15  99.68±1.2 
DBMF10 8.97±0.6    1154±4.24 0.44±0.08  5.84±0.16  100.19±1.6 
All values are expressed as mean±SD; (n=3) 
 
Table 6: Similarity (f2) and difference factor (f1
F. No. 
) with dissolution profile of all formulations 
f f1 Dissolution profiles 2 
DIRF 33.55 1 35.67 Dissimilar 
DIRF 27.95 2 39.23 Dissimilar 
DIRF 20.17 3 45.5 Dissimilar 
DIRF 18.39 4 48.14 Dissimilar 
DIRF 6.46 5 68.74 Similar 
DIRF 3.44 6 81.5 Similar 
DIRF 13.33 7 54.46 Similar 
DIRF 2.4 8 82.78 Similar 
DIRF 9.29 9 63.58 Similar 
DIRF 3.36 10 79.50 Similar 
DIRF 15.49 11 53.48 Similar 
DIRF 10.18 12 61.79 Similar 
Panda et al. 




All values are expressed as mean±SD; (n=3) 
Fig. 3: Comparative swelling studies of all the formulations of Doxofylline bilayer matrix tablets 
 
To optimise the immediate release layer for use in bilayer matrix 
tablet, the similarity and difference factors were calculated from the 
in vitro dissolution data of all the immediate release formulations by 
comparing with standard marketed formulation. Formulation DIRF1 
to DIRF4 showed dissimilarity in the dissolution profile whereas 
formulation DIRF5 to DIRF12 showed similarity in the dissolution 
profile. Among all the formulations, DIRF8 showed highest f2  value 
(82.78) and lowest f1
Based upon the highest f
 value (2.4) was considered as the best 
formulation. The dissolution profiles of all the batches of immediate 
release layer formulations calculated in the present investigation 
were presented in table 6. 
2  and lowest f1  values; DIRF8 formulation 
was identified as the optimised formulation and used as immediate 
release layer for the different formulations of Doxofylline bilayer 
sustained released matrix tablets. In order to optimise the in vitro 
drug release profile of Doxofylline bilayer sustained released matrix 
tablets; different hydrophilic matrix polymers viz., HPMC K4M, 
HPMC K15M and hydrophobic matrix polymer viz., Eudragit RSPO 
and Eudragit RLPO were used and ten different formulations were 
prepared. Between the two grades of HPMC used, HPMC K15M 
having better controlled release profile than HPMC K4M as it is 
having higher viscosity grade. It was observed that using HPMC 
polymer alone causes initial burst release because drug is 
hydrophilic in nature and maximum of the drug was released up to 8 
h. Because of that one more hydrophobic polymer i. e Eudragit was 
added to reduce the initial burst release of sustained release layer. 
Among the two grade of Eudragit used, Eudragit RSPO showed 
better sustained release effect than Eudragit RLPO. DBMF6
Further increase in the concentration of Eudragit, the initial release 
rate was much slower which was not desirable. So 8% of Eudragit 
was considered as optimum. The available marketed sustained 
release tablet containing 800 mg of Doxofylline had low initial 
release to elicit pharmacological action because drug is highly 
metabolised (80-90%) whereas the present formulation under study 
released around 44% of the drug within first hour that can be useful 
as loading dose. The loading dose can be used to elicit 
pharmacological action for acute asthma attack and the sustained 
release dose can be utilised as maintenance therapy so that it is not 
necessary to take repeated dose. So by using the present optimised 
formulation once daily medication is possible with proper 
management of disease conditions. The drug release profiles of 
different formulations were shown in fig. 4. 
 
formulation that contained 12.5% of HPMC K15M and 8% of 
Eudragit RSPO was considered as optimised formulation as the 
initial release was 44% as a loading dose within the first hour and 
further as sustained release upto 12 h.  
 
 
All values are expressed as mean±SD; (n=3) 
Fig. 4: In vitro release studies of all the formulations of Doxofylline bilayer tablets 
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The in vitro dissolution data of optimised formulation DBMF6 The release exponent ‘n’ for optimised formulation DBMF were 
fitted in different kinetic models viz. zero order, first order, Higuchi, 
Hixon-Crowell and Korse-Meyer Peppa’s kinetic model equation and 
the graphs were plotted those were shown fig. 5. The Hixon-Crowell 
plots was found to be fairly linear as indicated by it’s highest 
regression (0.989) values.  
6 was 
found to be 0.334 (n<0.5), which appears to indicate a quasi-fickian 
diffusion. So in present study in vitro drug release kinetic of 
optimised formulation of Doxofylline bilayer matrix tablets (DBMF6
 
) 
followed Hixon-Crowell release kinetic models and drug release 
mechanism is quasi-fickian diffusion. 
 
Fig. 5: In vitro release kinetic studies of optimised formulation (DBMF6
 
) Doxofylline bilayer matrix tablet 

















value of ‘n’ value of Peppa’s model  
DBMF 0.868 6 0.906 0.976 0.989 0.948 0.334 
 
Table 7: Comparison of in vitro dissolution data after stability studies at accelerated conditions of optimized batch (DBMF6
Time (h) 
) 
Initial After 15 d After 30 d After 45 d After 60 d After 90 d 
1 44.81±1.58 42.62±1.29 41.46±1.19 40.38±1.20 39.68±1.35 37.84±1.54 
2 49.57±1.81 47.19±1.89 46.28±1.77 44.56±1.36 42.66±1.24 40.52±1.28 
3 54.81±1.84 53.95±1.45 52.47±1.74 50.45±1.69 47.70±1.92 44.19±1.65 
4 59.52±1.73 57.78±1.59 58.62±1.61 57.19±1.53 55.81±1.84 52.86±1.47 
5 64.75±1.67 62.26±1.92 61.92±1.57 60.94±1.48 58.83±1.45 56.19±2.18 
6 70.42±1.57 67.22±1.71 66.58±1.92 64.18±1.84 62.94±1.54 59.55±1.36 
7 76.82±1.66 74.84±1.85 73.28±1.16 71.74±1.85 70.10±1.66 68.19±1.57 
8 81.60±1.45 79.69±1.94 78.51±1.78 76.59±1.74 74.95±1.76 73.59±2.30 
9 86.72±2.71 85.14±2.10 84.28±2.65 82.64±2.45 80.27±2.84 78.25±2.14 
10 91.38±2.84 89.87±2.41 88.51±2.62 85.38±2.52 83.19±2.52 80.85±2.25 
11 96.16±3.20 95.49±3.09 94.42±3.14 92.67±3.12 90.44±3.38 89.59±3.05 
12 99.42±3.56 98.58±3.17 97.19±3.46 94.19±3.44 92.68±3.51 90.08±3.10 
All values are expressed as mean±SD; (n=3) 
 
The optimised formulation of Doxofylline bilayer matrix tablets 
(DBMF6
CONCLUSION  
) did not show any significant change in physicochemical 
parameters like hardness, weight variation, friability, content 
uniformity and in vitro drug release characteristics. More than 90% 
of the drug had been retained that was confirmed through in vitro 
dissolution studies for 90 d after it had been stored under stressed 
condition. The results of in vitro release profile of optimised 
formulation at different time interval after storing it at accelerated 
stressed conditions were shown in table 7. 
In the present investigation Doxofylline bilayer matrix tablet was 
successfully developed. The major challenge in these studies was to 
design a bilayer matrix tablet of Doxofylline that can provide an 
initial loading dose followed by sustained release dose. Here cross 
carmellose and cross povidone were used as superdisintegrants for 
immediate release layer and different grade HPMC and Eudragit for 
sustained release layer of Doxofylline. The main objective of using 
hydrophobic polymer Eudragit with HPMC was to prevent the burst 
release effect the hydrophilic drug under study which was 
successfully developed. Formulation DBMF6 that contained 12.5% of 
HPMC K15M and 8% of Eudragit RSPO in SR layer with 4% of 
Polyplasdone-XL in immediate release layer showed 44% of drug 
release within first hour as a loading dose and sustained release 
upto 12 h with almost complete release (99%) emerged as 
optimised formulation. Increase in proportion of hydrophilic 
polymer caused initial burst release effect. Kinetic of in vitro drug 
release of optimized formulation DBMF6 found to be a mixed order 
kinetic as it obey almost first order within first one hour then it 
followed zero order release kinetic. The drug release mechanism 
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followed Hixon-Crowell cube root law with quasi-fickian diffusion. 
FTIR and DSC studies revelled that there is no chemical and thermal 
interaction between drug Doxofylline and excipients used for 
formulations. The accelerated stability studies were carried out for 
the optimised formulation and were found to be stable without any 
remarkable physicochemical changes. Thus from the results of the 
current study clearly indicate, a promising potential of the Doxofylline 
bilayer matrix tablets system as an alternative to the conventional 
dosage form as it enhance bioavailability of the Doxofylline by 
producing an initial loading dose followed by sustained release effect 
and can be therapeutically beneficial for acute and sustainable asthma. 
However, further clinical studies are needed to assess the utility of this 
system for patients suffering from asthma. 
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